MedPage Today: Clozapine's REMS Program on the Chopping Block at Upcoming FDA Meeting
Is a risk evaluation and mitigation strategy (REMS) still needed for clozapine? That's what a joint meeting of two FDA advisory committees will discuss on Tuesday. Risk management requirements for the ...
Healio: FDA: Prescribers must certify, enroll outpatients in new clozapine REMS by Nov. 15
FDA: Prescribers must certify, enroll outpatients in new clozapine REMS by Nov. 15
On September 15th, 2015, the US Food and Drug Administration (FDA) approved a new, shared risk evaluation and mitigation strategy (REMS) for the atypical antipsychotic medication clozapine in order to ...
Monthly Prescribing Reference: Issues With Patient Access to Clozapine Prompt REMS Update
The FDA has officially eliminated clozapine's risk evaluation and mitigation strategy (REMS) program, with all REMS operations stopped as of June 13. The announcement comes several months after a ...
Medscape: What are the components of the new REMS program, and how is it different from the previous programs? Dr Mathis: The new shared clozapine REMS program has similar components to the previous ...
The Food and Drug Administration (FDA) has announced that the full launch for the Clozapine Risk Evaluation and Mitigation Strategy (REMS) program will be postponed due to recent technical and ...
The US Food and Drug Administration (FDA) announced changes to its risk evaluation and mitigation strategy (REMS) for the antipsychotic drug clozapine, set to take effect on 28 February 2019.
Most physicians said the positives of clozapine's REMS outweighed its negatives. Most also said that mandatory blood testing was necessary, but it created a burden and medication delays. In 2024, an ...